Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is over

American Journal of Transplantation

Volumn 16, Issue 5, 2016, Pages 1345-1347

  Saxena, V ^a   Terrault, N A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; DACLATASVIR; DASABUVIR; ELBASVIR PLUS GRAZOPREVIR; EVEROLIMUS; INTERFERON; LEDIPASVIR; MULTIDRUG RESISTANCE PROTEIN; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RAPAMYCIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS;

ACUTE GRAFT REJECTION; CHRONIC HEPATITIS C; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROSIS; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER FUNCTION; LIVER GRAFT; PREVALENCE; PRIORITY JOURNAL; REVIEW; SURVIVAL; VIRAL CLEARANCE; HEPATITIS C;

HEPATITIS C; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84961266740     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13697     Document Type: Review

References (7)

1. Carbone M, Mutimer D, Neuberger J,. Hepatitis C virus and nonliver solid organ transplantation. Transplantation 2013; 95: 779-786.
2. Terrault NA, Adey DB,. The kidney transplant recipient with hepatitis C infection: Pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007; 2: 563-575.
3. Saxena V, Terrault N,. Current management of hepatitis C virus: Regimens for peri-liver transplant patients. Clin Liver Dis 2015; 19: 669-688.
4. Sawinski D, Kaur N, Ajeti A, et al., Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 2016; 16: 1588-1595.
5. Kamar N, Marion O, Rostaing L, et al., Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 2016; 16: 1474-1479.
6. Saxena V, Koraishy FM, Sise M, et al., Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-TARGET. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2015; Vienna, Austria. Abstract LP08.
7. Roth D, Nelson D, Bruchfeld A, et al., Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet 2015; 386: 1537-1545.